interferon alfa-2b


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to interferon alfa-2b: interferon alpha, interferon alfa-2a, Intron A

interferon

 [in″ter-fēr´on]
any of a family of glycoprotein biological response modifiers used as antineoplastic agents and immunoregulators; they inhibit cellular growth, alter the state of cellular differentiation, have effects on the cell cycle, interfere with oncogene expression, alter cell surface antigen expression, have effects on antibody production, and regulate cytotoxic effector cells.
interferon-α the major interferon produced by virus-induced leukocyte cultures; its primary producer cells are null cells, and its major activities are antiviral activity and activation of NK cells.
interferon alfa-2a a synthetic form of interferon-α produced by recombinant technology that acts as a biologic response modifier, used as an antineoplastic in the treatment of hairy cell leukemia and AIDS-related Kaposi's sarcoma; administered intramuscularly or subcutaneously.
interferon alfa-2b a synthetic form of interferon-α produced by recombinant technology that acts as a biologic response modifier, used in the treatment of veneral warts, hepatitis B, and chronic hepatitis C and as an antineoplastic in the treatment of hairy cell leukemia, malignant melanoma, non-Hodgkin's lymphomas, multiple myeloma, mycosis fungoides, and AIDS-related Kaposi's sarcoma; administered intramuscularly, subcutaneously, or intralesionally.
interferon alfacon-1 a synthetic interferon related to both α and β interferons, produced by recombinant DNA technology; used in the treatment of chronic hepatitis C virus infection, administered subcutaneously.
interferon alfa-n3 a highly purified mixture of natural human interferon proteins that acts as a biologic response modifier; used in the treatment of venereal warts, administered intralesionally.
interferon-β the major interferon produced by double-stranded RNA-induced fibroblast cultures; the major producer cells are fibroblasts, epithelial cells, and macrophages, and its major activity is antiviral.
interferon beta-1a a synthetic form of interferon-β produced by recombinant DNA techniques that acts as a biologic response modifier; used in the treatment of relapsing forms of multiple sclerosis; administered intramuscularly.
interferon beta-1b a synthetic modified form of interferon-β produced by recombinant DNA techniques; used as a biologic response modifier in the treatment of relapsing forms of multiple sclerosis; administered subcutaneously.
interferon-γ the major interferon produced by lymphocyte cultures that have been immunologically stimulated by mitogens or antigens; the major producer cells are T lymphocytes, and its major activity is immunoregulation.
interferon gamma-1b a synthetic form of interferon-γ produced by recombinant technology that acts as a biologic response modifier and antineoplastic. It is used to reduce the frequency and severity of serious infections associated with chronic granulomatous disease, administered subcutaneously.

interferon alfa-2b

n.
A synthetic form of interferon alpha produced by recombinant DNA technology, used in the treatment of chronic hepatitis B and C, hairy cell leukemia, malignant melanoma, follicular lymphoma, genital warts, and AIDS-related Kaposi's sarcoma.
References in periodicals archive ?
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Major Finding: In cirrhotic and noncirrhotic patients treated with boceprevir, pegylated interferon alfa-2b, and ribavirin, 57% of patients with cirrhosis and anemia treated with a ribavirin dose reduction had a sustained virologic response, compared with 64% of those treated with erythropoietin.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
Pegylated interferon alfa-2b or pegylated interferon alfa-2a in combination with ribavirin is the standard treatment for HCV infection, achieving response rates of 40% to 60% for patients with HCV genotype 1, (32) and higher rates for those with HCV genotypes 2 and 3.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C: a randomised trial.
Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial.
Among the goals of this clinical trial is to find the highest tolerable dose of VQD-001 combined with Interferon alfa-2b in the treatment of patients with advanced cancer that have not responded to standard treatment or where there is no standard treatment for that type of cancer.
HCV-796 interferes with the replication of hepatitis C virus (HCV), and the objectives of the trial are to assess its safety, tolerability, pharmacokinetic profile and antiviral activity when used in combination with pegylated interferon alfa-2b plus ribavirin, compared to the current standard of care in treatment-naive subjects with HCV genotype 1 infection and in patients with HCV genotype 1 infection who were non-responders to prior HCV therapy.
* There are several FDA-approved therapies for chronic hepatitis C: interferon alfa-2b, interferon alfa-2a, interferon alfacon-1, peginterferon alfa-2b, peginterferon alfa-2a, and each, except for interferon alfacon-1, in combination with ribavirin.
Although monotherapy showed no beneficial effects in the treatment of hepatitis C, it has a synergistic effect when used with interferon alfa-2b for the therapy of chronic hepatitis C.